MAZHAR KHOWAJA: Open Payments
NPI 1770523276 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$159,571 in 186 payments from 5 companies in 2025. Trend: 2023 $235,333 · 2024 $176,848 · 2025 $159,571
Speaker / faculty: $114,781Consulting: $23,750Travel & lodging: $16,736Food & beverage: $4,304
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 138 | $129,722 |
| ACADIA Pharmaceuticals Inc | 37 | $29,469 |
| Otsuka America Pharmaceutical, Inc. | 9 | $236 |
| E.R. Squibb & Sons, L.L.C. | 1 | $122 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
Products named: INGREZZA, NUPLAZID, REXULTI, COBENFY, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
